Skip to main content

Advertisement

SpringerLink
Log in

Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Erythropoiesis-stimulating agents (ESAs) have been shown to reduce the need for red blood cell (RBC) transfusions and to improve quality of life for cancer patients with anaemia. However, increased risks of mortality and disease progression have been reported when using ESAs with excessive target haemoglobin levels. In 2007, the United States Food and Drug Administration and Korea Food and Drug Administration issued regulatory alerts for using ESAs in cancer patients. Objective This retrospective study was performed to evaluate changes in ESA prescribing patterns between 2006 and 2010 and the impact on RBC transfusions in patients with solid tumours. Setting The Seoul National University Hospital (SNUH) in Korea. Methods This study includes adult patients with solid tumours who were diagnosed and treated in the SNUH from January 2006 to December 2010. The exclusion criterion was concomitant chronic renal failure. The patients’ Hb levels and prescription data for ESAs and RBC transfusions were statistically analysed. The number of inpatient and outpatient solid-tumour patients was also analysed as a baseline. Main outcome measure Prescription data on ESAs and RBC transfusion. Results After adjusting for the number of patient visits, the monthly mean ESA doses dispensed decreased by an average of 1,192 mcg per quarter over the last 5 years, and the number of RBC transfusions ordered increased by 3.77 instances per quarter. After correcting for the number of patients, the mean doses of ESA dispensed each month decreased by 3,190 mcg per quarter, and the number of RBC transfusions ordered increased by 9.51 instances per quarter. Conclusion During the last 5 years, the number of ESA doses dispensed at SNUH decreased and the number of RBC transfusions at SNUH increased, independent of the number of patients. The reduction in ESA use was thought to be due to the release of the safety alert letter in 2007. However, this study did not analyse other risk factors that may have influenced the number of RBC transfusions (e.g. metastatic cancer, comorbidities, surgery). Still, the results of this study suggest that the decreased ESA doses were relevant to the increased RBC transfusions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616–34.

    Article  PubMed  CAS  Google Scholar 

  2. Barrett-Lee PJ, Bailey NP, O’Brien ME, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000;82:93–7.

    Article  PubMed  CAS  Google Scholar 

  3. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–74.

    PubMed  CAS  Google Scholar 

  4. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204–14.

    Article  PubMed  CAS  Google Scholar 

  5. FDA. Postmarket drug safety information for patients and providers: information on erythropoiesis-stimulating agents (ESA) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp); 16 Feb 2010. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm109375.htm. Accessed 9 Feb 2012.

  6. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–60.

    Article  PubMed  CAS  Google Scholar 

  7. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960–72.

    Article  PubMed  CAS  Google Scholar 

  8. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027–32.

    Article  PubMed  CAS  Google Scholar 

  9. Jenkins JK. FDA news and events: erythropoiesis-stimulating agents (ESA); 26 June 2007. Available at http://www.fda.gov/NewsEvents/Testimony/ucm110908.htm. Accessed 9 Feb 2012.

  10. Korea Food and Drug Administration. ESA medicine safety letter distribution; 16 May 2007. Available at http://www.kfda.go.kr/index.kfda?mid=394&pageNo=11&seq=4178&cmd=v. Accessed 9 Feb 2012.

  11. Korea National Statistics Office. Korea Standard Classification of Disease; 1 Jan 2011. Available at http://kostat.go.kr/kssc/stclass/StClassAction.do?method=searchDisName&classKind=5&catgrp=kssc&catid1=kssc03&catid2=kssc03b. Accessed 9 Feb 2012.

  12. US Food and Drug Administration product label. Aranesp® (Darbepoetin alfa) For Injection; 16 Feb 2010.

  13. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among medicare patients with cancer. J Natl Cancer Inst. 2009;101:1633–41.

    Article  PubMed  CAS  Google Scholar 

  14. Central Cancer Registration Office. 2008 National Cancer Statistics; 28 Dec 2010. Available at http://naver.nanet.go.kr/SearchDetailView.do?cn=MONO1201129381&sysid=nhn. Accessed 9 Feb 2012.

  15. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts–blood transfusion. N Engl J Med. 1999;340:438–47.

    Article  PubMed  CAS  Google Scholar 

  16. Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs. 1989;38:863–99.

    Article  PubMed  CAS  Google Scholar 

  17. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2007;26:132–49.

    Article  PubMed  Google Scholar 

  18. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27:2838–47.

    Article  PubMed  CAS  Google Scholar 

  19. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer. 2008;99:14–22.

    Article  PubMed  CAS  Google Scholar 

  20. Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion. 2009;49:895–902.

    Article  PubMed  Google Scholar 

  21. Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer. 2011 [Epub 2011 Jan 24].

Download references

Conflicts of interest

None declared.

Author information

Authors and Affiliations

  1. College of Pharmacy, Kangwon National University, Kangwondaehak-gil 1, Chuncheon-si, Gangwon-do, 200-701, Korea

    Yu Jeung Lee

  2. Seoul National University Hospital, Seoul, Korea

    Rae Young Kang, Juyeun Lee, Yong Hwa Lee & Hye Suk Lee

  3. College of Medicine, Chung-Ang University, Seoul, Korea

    Ji Hoon Jeong

Authors
  1. Rae Young Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juyeun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong Hwa Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hye Suk Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ji Hoon Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Jeung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu Jeung Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kang, R.Y., Lee, J., Lee, Y.H. et al. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea. Int J Clin Pharm 34, 651–657 (2012). https://doi.org/10.1007/s11096-012-9660-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-012-9660-0

Keywords

Search

Navigation